Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336786 · ClinicalTrials.gov registry record · Phase 3
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
A Phase 3 study of Prostate Carcinoma, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT05336786 is a Phase 3 study of Prostate Carcinoma that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 70 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05336786, a Phase 3 study of Prostate Carcinoma, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.
Conditions Studied
Interventions
- DRUG Perflutren Lipid Microspheres
- PROCEDURE Ultrasound
Study Locations (2)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Other
- Amsterdam University Medical Centers - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336786
The ClinicalTrials.gov registry entry for NCT05336786 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Perflutren Lipid Microspheres is the first listed.
NCT05336786 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT05336786 about?
NCT05336786 is a clinical study titled "Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)". This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity ap...
What is the current status of trial NCT05336786?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2022-06-15. Estimated completion is 2026-05-26.
What conditions does trial NCT05336786 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT05336786?
The interventions under investigation include: Perflutren Lipid Microspheres (DRUG), Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT05336786?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336786 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
RECRUITING · Phase 3
-
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ACTIVE NOT RECRUITING · Phase 3
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
RECRUITING
-
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.